What clinical data supports the efficacy of Simtriyo in adults with ADHD?
The efficacy of Simtriyo in adults was evaluated in 2 identically designed, [br-d]short-term, randomized, double-blind, placebo-controlled trials in adults [br-d]aged 18 to 55.1,2 These studies demonstrated statistically significant [br-d]improvements in inattention and hyperactivity/impulsivity, as measured [br-d]by the AISRS total score at Day 42.1,2
Have clinical studies assessed the effect of Simtriyo on the associated features of ADHD in adults, such as emotional dysregulation and executive dysfunction?
A post hoc analysis studied the impact of Simtriyo on emotional [br-d]dysregulation and executive dysfunction, as measured by the ASRS [br-d]Expanded Version at Week 6.5,6
Has Simtriyo been studied over the long term in adults with ADHD?
In a 52-week open-label extension safety study, adults taking Simtriyo [br-d]showed no new safety findings and a low overall incidence of serious [br-d]adverse events.8
Of the 61.4% of patients who experienced an adverse event, most were [br-d]mild (45%) or moderate (36.1%). The most common treatment-[br-d]emergent adverse events were insomnia, nausea, diarrhea, and [br-d]headache.8
Patients also showed continued improvement in ADHD symptoms.8